(NASDAQ: BGNE) Beigene's forecast annual revenue growth rate of 26.07% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Beigene's revenue in 2024 is $2,458,779,000.On average, 4 Wall Street analysts forecast BGNE's revenue for 2024 to be $4,237,455,891,780, with the lowest BGNE revenue forecast at $4,099,748,078,294, and the highest BGNE revenue forecast at $4,498,680,919,719. On average, 4 Wall Street analysts forecast BGNE's revenue for 2025 to be $5,540,826,657,682, with the lowest BGNE revenue forecast at $5,170,092,839,550, and the highest BGNE revenue forecast at $6,154,349,144,921.
In 2026, BGNE is forecast to generate $6,659,688,367,362 in revenue, with the lowest revenue forecast at $6,576,917,123,745 and the highest revenue forecast at $6,760,315,457,662.